A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury - Wikidata - awgldk - TriplyDB

A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury

A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury

http://www.wikidata.org/entity/Q33836284

about

Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases Use of high-dose erythropoietin for repair after injury: A comparison of outcomes in heart and kidney.Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin Darbepoetin-mediated cardioprotection after myocardial infarction involves multiple mechanisms independent of erythropoietin receptor-common beta-chain heteroreceptor.The effect of erythropoietin on normal and neoplastic cells.Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?Carbamylated erythropoietin does not alleviate signs of dystrophy in mdx mice.Survival and proliferative roles of erythropoietin beyond the erythroid lineage.Erythropoietin protects epithelial cells from excessive autophagy and apoptosis in experimental neonatal necrotizing enterocolitis Anemia and heart failure: a cause of progression or only a consequence?β Common Receptor Mediates Erythropoietin-Conferred Protection on OxLDL-Induced Lipid Accumulation and Inflammation in Macrophages.Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis Erythropoietin and myocardial protection: what's new?The role of erythropoietin in myocardial protection: potential mechanisms and applications.Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors.Mechanisms of disease: erythropoietin--an old hormone with a new mission?Glutaraldehyde erythropoietin protects kidney in ischaemia/reperfusion injury without increasing red blood cell production.Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care Experimental models of acute renal failure and erythropoietin: what evidence of a direct effect?Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver.Erythropoietin in chronic heart failure.Systems approaches to preventing transplanted cell death in cardiac repair.Darbepoetin alfa exerts a cardioprotective effect in autoimmune cardiomyopathy via reduction of ER stress and activation of the PI3K/Akt and STAT3 pathways.Darbepoetin-alpha prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure.Suppression of coronary atherosclerosis by helix B surface Peptide, a nonerythropoietic, tissue-protective compound derived from erythropoietin.G-CSF- and erythropoietin-based cell therapy: a promising strategy for angiomyogenesis in myocardial infarction.Erythropoietin and a nonerythropoietic peptide analog promote aortic endothelial cell repair under hypoxic conditions: role of nitric oxide.Cellular basis of uraemic cardiomyopathy: a role for erythropoietin?Emerging technologies in the delivery of erythropoietin for therapeutics.Non-erythropoietic tissue-protective peptides derived from erythropoietin: WO2009094172.Treating anemia in heart failure patients: a review of erythropoiesis-stimulating agents.Bench to bedside: A role for erythropoietin in sepsis.Erythropoietin and the heart: facts and perspectives.Erythropoiesis-stimulating agents and heart failure.Erythropoietin: a future therapy for failing hearts?Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease.Anemia and iron deficiency in heart failure.What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials.

P2860

Q28388335-C0A2E1CC-A926-4309-952D-87516235497C Q30486662-8CEB8A5C-63A2-4362-9A57-A91B8FB22A49 Q34069738-D13601A6-07CD-4CB8-A449-F637B2BD77D8 Q34219629-E92514B5-F847-43F9-A00F-AE22C2DD8B55 Q34291437-668864CA-727E-4BAB-84DA-5773C260043A Q34504572-691B1C3B-4557-434E-9A27-92438FB2F349 Q34674989-6F45E094-72A8-42BC-9E35-E7CC71718059 Q34725972-0AD2E911-ADAA-41F7-B325-7354F0ED708E Q34920664-9A362D4B-B21E-43D5-88F8-D8782B831020 Q35252704-321F3804-2C11-4C2E-86A4-2390D2E7D782 Q35691522-E8DE8C46-1D4F-472B-BA72-00E89F6592A2 Q35768736-1AFA5B98-C9A9-40EB-8460-96D8E3F45A5A Q35797921-CBD25B15-0CB4-46BC-BD48-5981A9AFDAD4 Q35798280-87FAE249-2994-4F6B-8D29-2541BC0CD2EF Q36191300-8E22939B-E401-4F43-8650-0A465C446A58 Q36352011-03343D42-93C6-48BA-9257-85C69F139973 Q36555238-33F7A30F-D032-4B95-A557-EC2145A85E8F Q36600985-6F82C4E9-6E07-4990-B05C-03C23FAB47E2 Q36603218-A460DB68-CE28-4381-BE69-86E4259BB239 Q36633772-D3B255D7-C7A2-45A7-A292-0E7C189B48A1 Q36819627-9EAD2775-671F-4010-B76B-794F6D72D504 Q36915712-2D47C869-784F-4C0B-8AD3-D2BCEB4BCCFD Q36961380-F70E6A60-676A-42F6-8A92-98C6D1616654 Q36984663-451B50AE-4F5E-47FA-B8A6-88AF7E8B56D8 Q37008467-7E7F0C91-06B2-41E7-ADAD-0435464E91D2 Q37038709-36AF7158-FA7C-478D-BA67-013D751D4CFF Q37100284-18E376CC-4603-4C3F-9283-7A9D3D6E83BE Q37176449-9E255AB9-44AE-49B4-B910-04A4B6B5495B Q37376670-A7E95DA8-5FC7-4C25-B4AB-AB2DCFD83245 Q37562631-D1970E0F-8B2E-4EB7-AB2F-8E1C6801E71D Q37646523-32EDA3B1-A474-42C3-BB10-B59B4E5CACA4 Q37700755-FD28E8AD-B50E-48D7-850A-E4AFE215E297 Q37765902-83522EED-97E9-483B-B47A-7C762F1460A2 Q37781412-C9086BCE-3692-4D5C-BC68-0436AC9C9DF2 Q37798565-1589F99B-831F-4938-BBDA-E81FACF3D109 Q37802925-D9BE20A8-9248-49A5-AEDD-47BCD4542088 Q37952603-68FB72F3-C385-4D36-813D-A7591C40D38B Q38037120-FA34246F-65B5-4778-8202-2DF4D9EA4084 Q38039849-38447C4B-BF75-481D-BDAE-B45C77C1B759 Q38108537-F4C7076F-9389-4B0E-B984-9CBAA1978597

P2860

A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury

http://www.wikidata.org/entity/Q33836284

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

A nonerythropoietic derivative ...... om ischemia-reperfusion injury

@ast

A nonerythropoietic derivative ...... om ischemia-reperfusion injury

@en

type

label

A nonerythropoietic derivative ...... om ischemia-reperfusion injury

@ast

A nonerythropoietic derivative ...... om ischemia-reperfusion injury

@en

prefLabel

A nonerythropoietic derivative ...... om ischemia-reperfusion injury

@ast

A nonerythropoietic derivative ...... om ischemia-reperfusion injury

@en

P1433

Q33836284-3A9FB7B9-6ADA-4AAA-B1C4-C2A1BF8F13E5

P1476

Q33836284-7461BB98-D533-4AB7-9F0E-359D273B6FD2

P2093

Q33836284-0875392B-586A-458A-8B20-3FFF05760B67

Q33836284-123054D9-6DB6-4667-94B2-77958601959B

Q33836284-16B5FBBF-F41A-40E4-94B0-7AB887678450

Q33836284-2EA7C859-92C5-41DF-A9FD-15C53BF00CC1

Q33836284-4751EF62-D9A1-4F55-B41C-DDB0CBFF33BD

Q33836284-56B2AC68-086D-4F41-81A1-30E6435E6EE4

Q33836284-67A171D8-A5C1-479D-AE92-FA567BC7981D

Q33836284-7A085B7F-8A7B-42E4-9F1D-B119557BC48E

Q33836284-8774A4EF-5D20-48D6-A5AF-4419BA2EB9C1

Q33836284-8C591C9A-2895-4900-9762-89EBF5E24561

P2860

Q33836284-00F540C8-1232-4C27-AD92-6FEB612F1BDB

Q33836284-01BEB654-9B74-47DA-A1D0-3E74379E23AD

Q33836284-06B85DBF-D824-494C-B755-4A636A637B84

Q33836284-0F11B6FE-4774-46CB-9336-35D3963D464A

Q33836284-1133A253-CEFE-43B4-BB76-51E6F60A5C25

Q33836284-14E42A43-C569-4877-B222-9C9FF1FCD068

Q33836284-184D22AD-A7CD-45E6-98A9-27194A96D55B

Q33836284-1B6C42D7-ACDD-4804-AFAF-0E4CA5648CC2

Q33836284-1E43F6F1-405F-4C56-9D1A-ABE064468B9F

Q33836284-2143FE3B-EE09-41EF-9813-6E00F9A937A6

P304

Q33836284-C5781BB0-63BE-4664-B70E-6C86837CF3FF

P31

Q33836284-CCB1350D-91AF-4AC7-9CBA-C9EB24B587AC

P356

Q33836284-52C549A2-E953-415A-9671-B6CE3ED90217

P407

Q33836284-53B7F984-A188-4CFC-B16E-F3A7890805FC

P433

Q33836284-369AD333-6943-4E99-A249-12BAA1ACE610

P478

Q33836284-2FDBCD11-B59A-4ACA-876F-F3915B539AB2

P577

Q33836284-DA75ED9B-B21D-4BDB-84DE-218A7F5DCA9C

P5875

Q33836284-9ACC9FF1-6B0C-43F1-95C1-73E119F708AA

P698

Q33836284-4253FB9E-35D2-4D6B-8E9E-030BCDF65DC9

P921

Q33836284-9312A114-31C6-478E-956C-896FDD54723F

Q33836284-A8C159E1-EACC-4FAF-852A-1D836DE7651A

P932

Q33836284-6F3A0A25-7F56-4A9E-8D00-40CA67905306

P356

PNAS.0409329102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

A nonerythropoietic derivative ...... om ischemia-reperfusion injury

@en

P2093

Anthony Cerami

http://www.w3.org/2001/XMLSchema#string

Antonio Bai

http://www.w3.org/2001/XMLSchema#string

Eleonora Carlo

http://www.w3.org/2001/XMLSchema#string

Fabio Fiordaliso

http://www.w3.org/2001/XMLSchema#string

Ivan Cuccovillo

http://www.w3.org/2001/XMLSchema#string

Lidia Staszewsky

http://www.w3.org/2001/XMLSchema#string

Manuela Mengozzi

http://www.w3.org/2001/XMLSchema#string

Michael Brines

http://www.w3.org/2001/XMLSchema#string

Mirko Doni

http://www.w3.org/2001/XMLSchema#string

Pietro Ghezzi

http://www.w3.org/2001/XMLSchema#string

P2860

Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats.

Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death.

Reperfusion injury induces apoptosis in rabbit cardiomyocytes.

Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling.

Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo.

Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin.

Erythropoietin both protects from and reverses experimental diabetic neuropathy.

An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection.

Myocardial response to infarction in the rat. Morphometric measurement of infarct size and myocyte cellular hypertrophy.

Role of apoptosis in remodeling after myocardial infarction.

P304

2046-2051

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0409329102

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8060975

http://www.w3.org/2001/XMLSchema#string

P698

15671158

http://www.w3.org/2001/XMLSchema#string

P921

reperfusion injury

P932

548534

http://www.w3.org/2001/XMLSchema#string